This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Here's Why HealthEquity (HQY) is Poised for a Turnaround After Losing 7.7% in 4 Weeks
by Zacks Equity Research
HealthEquity (HQY) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Here's Why You Should Hold on to Accuray (ARAY) Stock For Now
by Zacks Equity Research
Investors continue to be optimistic about Accuray (ARAY) owing to its solid global reach.
Catalent (CTLT) Inks Deal With MigVax for Oral COVID-19 Vaccine
by Zacks Equity Research
Catalent's (CTLT) latest agreement is expected to significantly boost global COVID-19 vaccination drives.
BD's (BDX) New Tie-Up to Develop Detection Kit for Monkeypox
by Zacks Equity Research
BD's (BDX) partnership with CerTest is expected to aid in advancing the understanding of the monkeypox virus' global spread.
BD (BDX) to Expand Base in Pharmacy Automation With New Buyout
by Zacks Equity Research
BD's (BDX) buyout of Parata Systems is expected to advance its 2025 strategy to accelerate innovation in smart, connected care and enabling new care settings.
HealthEquity (HQY) Q1 Earnings Lag Estimates, FY23 View Up
by Zacks Equity Research
HealthEquity (HQY) witnesses solid growth in HSAs, besides recording robust segmental revenues, in the first quarter of fiscal 2023.
Here's Why You Should Hold on to Avanos (AVNS) Stock For Now
by Zacks Equity Research
Investors continue to be optimistic about Avanos (AVNS) owing to its strong product line and focus on R&D.
HealthEquity (HQY) Q1 Earnings Miss Estimates
by Zacks Equity Research
HealthEquity (HQY) delivered earnings and revenue surprises of -3.57% and 1.46%, respectively, for the quarter ended April 2022. Do the numbers hold clues to what lies ahead for the stock?
Assure Holdings Corp. (IONM) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Assure Holdings Corp. (IONM) delivered earnings and revenue surprises of -216.67% and 27.68%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
VYNE Therapeutics Inc. (VYNE) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
VYNE Therapeutics Inc. (VYNE) delivered earnings and revenue surprises of 6.67% and 67.64%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
InnovAge Holding Corp. (INNV) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
InnovAge Holding Corp. (INNV) delivered earnings and revenue surprises of -300% and 5.40%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Viatris (VTRS) Q1 Earnings Beat Estimates
by Zacks Equity Research
Viatris (VTRS) delivered earnings and revenue surprises of 14.81% and 0.12%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
HealthEquity (HQY) Q4 Earnings Lag Estimates, Margins Down
by Zacks Equity Research
HealthEquity (HQY) witnesses solid growth in HSAs, along with recording robust Custodial and Interchange revenues, in the fourth quarter of fiscal 2022.
HealthEquity (HQY) Q4 Earnings Miss Estimates
by Zacks Equity Research
HealthEquity (HQY) delivered earnings and revenue surprises of -4.76% and 2.02%, respectively, for the quarter ended January 2022. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: HealthEquity (HQY) Q4 Earnings Expected to Decline
by Zacks Equity Research
HealthEquity (HQY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
DermTech, Inc. (DMTK) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
DermTech, Inc. (DMTK) delivered earnings and revenue surprises of -20.55% and 5.97%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
GoodRx Holdings, Inc. (GDRX) Lags Q4 Earnings and Revenue Estimates
by Zacks Equity Research
GoodRx Holdings, Inc. (GDRX) delivered earnings and revenue surprises of -10% and 1.57%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
ModivCare (MODV) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
ModivCare (MODV) delivered earnings and revenue surprises of 28.66% and 4.12%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Abbott (ABT) Gets FDA Approval for CardioMEMS HF System
by Zacks Equity Research
Abbott's (ABT) CardioMEMS HF System will enable physicians to monitor for early warning signs of worsening heart failure before it progresses to a later stage.
Here's Why You Should Hold on to STERIS (STE) Stock for Now
by Zacks Equity Research
Investors are optimistic about STERIS (STE) on its better-than-expected earnings in the fiscal third quarter and the ongoing integration of the Cantel Medical business.
Here's Why You Should Hold on to IDEXX (IDXX) Stock for Now
by Zacks Equity Research
Robust domestic and international performances by the CAG arm are driving IDEXX's (IDXX) fourth-quarter top line.
Tandem Diabetes (TNDM) to Offer Insulin Delivery With Smartphone
by Zacks Equity Research
Tandem Diabetes' (TNDM) t:connect is the first-ever app on both iOS and Android operating systems to receive FDA clearance for insulin delivery from a personal smartphone.
OPKO's (OPK) NGENLA to Offer GHD Treatment in European Union
by Zacks Equity Research
OPKO's (OPK) marketing authorization for NGENLA in the European Union stands to benefit children and adolescents affected by growth hormone deficiency.
Here's Why You Should Hold on to Thermo Fisher (TMO) Stock Now
by Zacks Equity Research
Investors are optimistic about Thermo Fisher's (TMO) better-than-expected fourth-quarter results and impressive COVID-19 response-related revenues.
HealthEquity (HQY) Up 10.3% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
HealthEquity (HQY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.